-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KYV-101 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KYV-101 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KYV-101 in Primary Progressive Multiple Sclerosis (PPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KYV-101 in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KYV-101 in Lupus Nephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KYV-101 in Lupus Nephritis Drug Details: KYV-101 is under development for...
-
Product Insights
Likelihood of Approval Analysis for Disruptive Behavior Disorder
Overview How likely is it that the drugs in Disruptive Behavior Disorder will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disruptive Behavior Disorder Overview Disruptive Behavior Disorders (DBD) encompass conditions like...
-
Sector Analysis
NewAttention Deficit Hyperactivity Disorder (ADHD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Attention Deficit Hyperactivity Disorder (ADHD) Market Report Overview The ADHD market across the 7MM was valued at $11.9 billion in 2022. The market will decline at a CAGR of less than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with specific criteria for children and adults. ADHD is characterized by age-inappropriate, extreme, and impairing levels of inattention and/or hyperactivity and impulsivity. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avelumab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avelumab in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avelumab in Metastatic Colorectal Cancer Drug Details: Avelumab (MSB-0010718C, Bavencio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naltrexone Hydrochloride in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naltrexone Hydrochloride in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naltrexone Hydrochloride in Crohn's Disease (Regional Enteritis) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGEN-2373 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGEN-2373 in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGEN-2373 in Sarcomas Drug Details: AGEN-2373 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGEN-2373 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGEN-2373 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGEN-2373 in Breast Cancer Drug Details: AGEN-2373 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KYV-101 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KYV-101 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KYV-101 in Systemic Sclerosis (Scleroderma) Drug Details: KYV-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTA-101 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTA-101 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTA-101 in Diffuse Large B-Cell Lymphoma Drug Details: CTA-101 is...